SCHEMBL2694003

SCHEMBL2694003

Cn1cccc1CN(Cc1ccc(CN2CCC3(CCN(C4CCCCC4)CC3)C2)cc1)Cc1ncc[nH]1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 4/20 0.43
CYP3A4 P08684 9/20 0.36
CYP2D6 P10635 7/20 0.36
CYP1A2 P05177 5/20 0.36
CYP2C19 P33261 4/20 0.36
CYP2C9 P11712 4/20 0.36
ALDH1A1 P00352 3/20 0.36
TSHR P16473 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
USP2 O75604 1/20 0.33
KDM4E B2RXH2 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
KCNH2 Q12809 1/20 0.31
KDM1A O60341 1/20 0.31
MAOB P27338 1/20 0.31
RCOR1 Q9UKL0 1/20 0.31
CCR4 P51679 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1793097 0.90 CXCR4 (0.49) CXCR4CYP3A4CYP2D6CYP1A2CYP2C19
SCHEMBL2695146 0.89 CXCR4 (0.46) CXCR4CYP3A4CYP2D6ALDH1A1TSHR
SCHEMBL2694762 0.88 CXCR4 (0.49) CXCR4CYP3A4CYP2D6CYP1A2CYP2C19
SCHEMBL2695579 0.87 CXCR4 (0.46) CXCR4CYP3A4CYP2D6CYP1A2CYP2C19
SCHEMBL14856676 0.87 CXCR4 (0.45) CXCR4CYP3A4CYP2D6CYP1A2CYP2C19
SCHEMBL2694965 0.85 CXCR4 (0.45) CXCR4CYP3A4CYP2D6CYP1A2CYP2C19
SCHEMBL5926512 0.85 CXCR4 (0.46) CXCR4CYP2D6ALDH1A1TSHRMEN1
SCHEMBL2694387 0.85 CXCR4 (0.43) CXCR4CYP3A4CYP2D6CYP2C9ALDH1A1
SCHEMBL2694598 0.85 CXCR4 (0.46) CXCR4CYP3A4CYP2D6ALDH1A1TSHR
SCHEMBL2695656 0.84 CXCR4 (0.45) CXCR4CYP3A4CYP2D6CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP claimed
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US disclosed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP disclosed
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-08-16 US disclosed
US-8168783-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-05-01 US disclosed
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2009-07-02 US disclosed
EP-1961744-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885CYP3A4 3747/4885CYP2D6 2687/4885
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR3, CXCR1 CXCR4 1/4885CYP3A4 4052/4885CYP2D6 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.